Nutritional Composition for Brain Atrophy Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current nutritional interventions have not adequately addressed the progression and prevention of brain atrophy, particularly in neurodegenerative diseases like Alzheimer's, where brain volume loss and cognitive impairment are significant concerns.
Innovation Solution
A composition comprising therapeutically effective amounts of uridine monophosphate (UMP), docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), vitamin E, vitamin C, selenium, vitamin B6, vitamin B9, vitamin B12, and choline, administered to slow down brain atrophy progression and preserve brain volume in individuals at risk of neurodegenerative disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nutritional intervention is implemented to prevent brain atrophy, then brain volume preservation and cognitive function maintenance are improved, but the complexity of the treatment composition increases
Solution Approach 1:
The patent combines multiple nutritional components (uridine, omega-3 fatty acids, choline, B vitamins, antioxidants) into a single integrated composition. This merging approach addresses brain atrophy through synergistic action of multiple nutrients while simplifying the treatment protocol for patients, resolving the contradiction between effective brain volume preservation and treatment complexity
Solution Approach 2:
The invention uses a composite nutritional formulation containing five distinct groups of active ingredients working together. This composite approach allows each component to contribute specific functions (membrane synthesis, neuroprotection, cognitive support) while collectively achieving comprehensive brain atrophy prevention, balancing effectiveness with a unified treatment solution
2Reliability
If a comprehensive nutritional composition is used to treat brain atrophy, then cognitive function and memory improvement are enhanced, but the cost and complexity of administration increase
Solution Approach 1:
By consolidating multiple essential nutrients into one composition, the patent makes administration straightforward for patients while maintaining comprehensive cognitive support. The merged formulation eliminates the need for patients to take multiple separate supplements, improving ease of operation without sacrificing therapeutic effectiveness
Data Source
AI summary
The invention pertains to the use of therapeutically effective amounts of (i) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof; and(ii) at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA), or esters thereof; and (iii) vitamin C and/or selenium, optionally in combination with vitamin E, in the manufacture of a product for therapeutically preventing and/or slowing down brain atrophy in a human subject in need thereof.